Sanofi (NASDAQ:SNY) Position Boosted by Todd Asset Management LLC

Todd Asset Management LLC increased its stake in shares of Sanofi (NASDAQ:SNY - Free Report) by 8.7% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 383,241 shares of the company's stock after purchasing an additional 30,749 shares during the period. Todd Asset Management LLC's holdings in Sanofi were worth $19,059,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Rise Advisors LLC grew its stake in shares of Sanofi by 98.4% during the 4th quarter. Rise Advisors LLC now owns 506 shares of the company's stock valued at $25,000 after purchasing an additional 251 shares during the period. Salem Investment Counselors Inc. bought a new stake in Sanofi during the fourth quarter valued at approximately $27,000. Venturi Wealth Management LLC increased its holdings in Sanofi by 163.5% during the fourth quarter. Venturi Wealth Management LLC now owns 535 shares of the company's stock valued at $27,000 after buying an additional 332 shares during the last quarter. McIlrath & Eck LLC raised its position in Sanofi by 143.3% in the fourth quarter. McIlrath & Eck LLC now owns 613 shares of the company's stock worth $30,000 after acquiring an additional 361 shares during the period. Finally, CNB Bank purchased a new position in shares of Sanofi during the 3rd quarter worth $39,000. Institutional investors own 10.04% of the company's stock.

Sanofi Price Performance

Shares of NASDAQ SNY traded down $0.45 during mid-day trading on Friday, reaching $49.01. The company's stock had a trading volume of 1,113,911 shares, compared to its average volume of 2,757,247. The stock has a fifty day moving average of $47.90 and a two-hundred day moving average of $48.23. The firm has a market capitalization of $123.98 billion, a PE ratio of 24.63, a P/E/G ratio of 1.38 and a beta of 0.61. Sanofi has a 52 week low of $42.63 and a 52 week high of $55.93. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.27 and a quick ratio of 0.87.

Sanofi (NASDAQ:SNY - Get Free Report) last announced its quarterly earnings data on Thursday, February 1st. The company reported $0.89 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.94 by ($0.05). Sanofi had a net margin of 10.52% and a return on equity of 19.69%. The company had revenue of $11.76 billion for the quarter, compared to analysts' expectations of $13.02 billion. As a group, sell-side analysts anticipate that Sanofi will post 4.12 EPS for the current fiscal year.

Sanofi Increases Dividend

The business also recently declared an annual dividend, which will be paid on Thursday, June 6th. Shareholders of record on Friday, May 10th will be issued a $1.478 dividend. This is an increase from Sanofi's previous annual dividend of $1.38. This represents a yield of 2.98%. The ex-dividend date is Thursday, May 9th. Sanofi's payout ratio is currently 69.35%.

Analysts Set New Price Targets

SNY has been the topic of several analyst reports. TheStreet downgraded Sanofi from a "b" rating to a "c" rating in a research report on Friday, February 9th. Morgan Stanley began coverage on Sanofi in a research note on Tuesday, January 23rd. They set an "equal weight" rating and a $55.00 price objective for the company. Finally, StockNews.com cut shares of Sanofi from a "strong-buy" rating to a "buy" rating in a research note on Tuesday, February 27th. Three research analysts have rated the stock with a hold rating and three have issued a buy rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $55.00.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.